The firm has randomized participants in the REGENERATE-PD study of AB-1005 in the UK and Poland, with plans to expand to Germany next.
Regulators in the UK also approved the IDH1/2 inhibitor last week, making it the first precision targeted treatment in Europe for this post-surgery setting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback